Senti Biosciences Sells Certain Assets to Celadon Partners

Palo Alto – August 14, 2023 – Cooley advised Senti Biosciences, a biotechnology company, on its sale of certain assets – including its manufacturing facility and chemistry, manufacturing, and controls capabilities – to Celadon Partners to establish GeneFab. Cooley lawyers Maureen Nagle, Luke Blackett and Chrystal Cantrelle led the team advising on M&A, while Rena Kaminsky and Freddy Yip led the life sciences partnering team, and Peter Crain and Alanna Zuchelli led the real estate team.

Senti Bio is eligible to receive approximately $38 million in cash by the end of 2025 – with approximately $18.9 million due at closing and the remaining $18.9 million to be paid in installments in 2024 and 2025, subject to satisfaction of certain conditions – as well as an $8 million in manufacturing credit. The sale will enhance Senti Bio’s focus on advancing its oncology programs.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.